• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.

作者信息

Tibben J G, Boerman O C, Claessens R A, Corstens F H, van Deuren M, de Mulder P H, van der Meer J W, Keijser K G, Massuger L F

出版信息

J Natl Cancer Inst. 1993 Jun 16;85(12):1003-4. doi: 10.1093/jnci/85.12.1003.

DOI:10.1093/jnci/85.12.1003
PMID:8496973
Abstract
摘要

相似文献

1
Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.静脉注射双特异性抗体OC/TR F(ab')2后一名卵巢癌患者体内的细胞因子释放情况
J Natl Cancer Inst. 1993 Jun 16;85(12):1003-4. doi: 10.1093/jnci/85.12.1003.
2
Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.用于癌症患者静脉治疗的双特异性单克隆抗体：免疫生物学方面
J Hematother. 1995 Oct;4(5):409-14. doi: 10.1089/scd.1.1995.4.409.
3
Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.嵌合双特异性OC/TR单克隆抗体介导表达叶酸结合蛋白（MOv18）的肿瘤细胞裂解，并在患者中显示出降低的免疫原性。
J Immunother. 1997 Nov;20(6):496-504. doi: 10.1097/00002371-199711000-00010.
4
Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.在接受双特异性单克隆抗体（bsAb）靶向激活T淋巴细胞治疗的卵巢癌患者中，人抗鼠抗体对bsAb靶向细胞溶解的抑制作用。
Int J Cancer. 1995 Feb 8;60(4):450-7. doi: 10.1002/ijc.2910600405.
5
Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients.静脉注射双特异性单克隆抗体OC/TR F(ab')2在卵巢癌患者中的药代动力学、生物分布及生物学效应
Int J Cancer. 1996 May 16;66(4):477-83. doi: 10.1002/(SICI)1097-0215(19960516)66:4<477::AID-IJC11>3.0.CO;2-5.
6
Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.使用CD3 x EGP-2导向双特异性单克隆抗体BIS-1治疗肺癌的方法。
Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):203-6. doi: 10.1007/s002620050433.
7
T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.抗CD3双特异性抗体治疗中的T细胞活化和细胞因子产生
J Hematother. 1995 Oct;4(5):395-402. doi: 10.1089/scd.1.1995.4.395.
8
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.通过双特异性单克隆抗体重新靶向的自体T淋巴细胞进行腹腔内治疗使晚期卵巢癌消退。
J Natl Cancer Inst. 1995 Oct 4;87(19):1463-9. doi: 10.1093/jnci/87.19.1463.
9
Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.抗CD3×抗肿瘤F(ab')2双功能抗体激活并重新靶向肿瘤浸润淋巴细胞。
J Immunol. 1995 Aug 1;155(3):1296-303.
10
Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody.通过双特异性单克隆抗体重新靶向的自体T淋巴细胞腹腔内治疗晚期卵巢癌可实现局部而非全身免疫调节。
Int J Cancer. 1997 Oct 9;73(2):211-9. doi: 10.1002/(sici)1097-0215(19971009)73:2<211::aid-ijc9>3.0.co;2-z.

引用本文的文献

1
Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies.开发一种用于检测 T 细胞依赖性双特异性抗体中 T 细胞激活杂质的生物测定法。
Sci Rep. 2019 Mar 7;9(1):3900. doi: 10.1038/s41598-019-40689-1.
2
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.使用双特异性 NK 受体融合蛋白的癌症免疫疗法，该融合蛋白同时结合 T 细胞和肿瘤细胞。
Cancer Res. 2011 Mar 15;71(6):2066-76. doi: 10.1158/0008-5472.CAN-10-3200. Epub 2011 Jan 31.
3
T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.
由CD19xCD3双特异性单链抗体诱导的T细胞介导的B细胞裂解是穿孔素依赖性的且不依赖死亡受体。
Cancer Immunol Immunother. 2004 Jul;53(7):625-32. doi: 10.1007/s00262-003-0496-2. Epub 2004 Feb 6.
4
Targeting of peripheral blood T lymphocytes.外周血T淋巴细胞的靶向作用。
Springer Semin Immunopathol. 1996;18(2):211-26. doi: 10.1007/BF00820667.
5
Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.嵌合双特异性G250/抗CD3单克隆抗体的产生，一种对抗肾细胞癌的工具。
Br J Cancer. 1996 Sep;74(5):735-44. doi: 10.1038/bjc.1996.430.
6
Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.静脉注射双特异性抗体在接受皮下注射白细胞介素-2的肾细胞癌患者中的I期研究。
Br J Cancer. 1994 Oct;70(4):652-61. doi: 10.1038/bjc.1994.366.
7
Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo.双特异性抗体在体外和体内将小鼠T细胞细胞毒性重新导向同基因乳腺癌。
Cancer Immunol Immunother. 1995 Mar;40(3):182-90. doi: 10.1007/BF01517350.
8
Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.静脉注射BIS-1 F(ab')2对肾细胞癌患者的免疫调节作用。
Br J Cancer. 1995 Sep;72(3):795-9. doi: 10.1038/bjc.1995.414.
9
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.一种以功能性单链分子形式表达的具有高肿瘤细胞细胞毒性的小型双特异性抗体构建体。
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7021-5. doi: 10.1073/pnas.92.15.7021.
10
CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.非霍奇金淋巴瘤患者静脉注射CD3×CD19双特异性抗体后CD8 T细胞的激活
Cancer Immunol Immunother. 1995 Jun;40(6):390-6. doi: 10.1007/BF01525390.